Bain Capital's healthcare SPAC BCLS Acquisition prices $125 million IPO at $10

BCLS Acquisition, a blank check company formed by Bain Capital Life Sciences targeting the healthcare industry, raised $125 million by offering 12.5 million shares at $10. The SPAC did not offer warrants that would become exercisable following completion of the initial business combination. It may raise an additional $25 million at the closing of an acquisition pursuant to a forward purchase agreement with its sponsor.

The company is led by co-founders and Managing Directors of Bain Capital Life Sciences, Chairman Adam Koppel and CEO and Director Jeffrey Schwartz. The company plans to target the healthcare industry, particularly businesses primarily based in North America and Europe in the biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology fields.

BCLS Acquisition plans to list on the Nasdaq under the symbol BLSA. Goldman Sachs and Jefferies acted as joint bookrunners on the deal.

The article Bain Capital's healthcare SPAC BCLS Acquisition prices $125 million IPO at $10 originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.